Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Accounts Payables: 2016-2024

Historic Accounts Payables for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $15.2 million.

  • Akebia Therapeutics' Accounts Payables fell 25.25% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 25.25%. This contributed to the annual value of $15.2 million for FY2024, which is 3.72% up from last year.
  • As of FY2024, Akebia Therapeutics' Accounts Payables stood at $15.2 million, which was up 3.72% from $14.6 million recorded in FY2023.
  • Akebia Therapeutics' Accounts Payables' 5-year high stood at $41.3 million during FY2020, with a 5-year trough of $14.6 million in FY2023.
  • In the last 3 years, Akebia Therapeutics' Accounts Payables had a median value of $15.2 million in 2024 and averaged $15.9 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first grew by 5.33% in 2020, then slumped by 46.35% in 2022.
  • Over the past 5 years, Akebia Therapeutics' Accounts Payables (Yearly) stood at $41.3 million in 2020, then dropped by 18.69% to $33.6 million in 2021, then crashed by 46.35% to $18.0 million in 2022, then decreased by 18.79% to $14.6 million in 2023, then grew by 3.72% to $15.2 million in 2024.